Evolent Health (EVH) Net Income towards Common Stockholders (2014 - 2026)

Evolent Health's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$26.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 63.14% year-over-year to -$26.6 million in Q1 2026; TTM through Mar 2026 was -$533.8 million, a 279.97% decrease from a year earlier, with the FY2025 full-year figure at -$579.4 million, down 519.99% from the prior year.
• Net Income towards Common Stockholders advanced to -$26.6 million in Q1 2026 per EVH's latest filing, from -$429.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $2.1 million in Q3 2022 and bottomed at -$429.1 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$26.9 million (2025), against an average of -$50.6 million.
• Across the five-year window, Net Income towards Common Stockholders soared 116.28% in 2022 and plunged 1663.64% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$11.3 million in 2022, then tumbled by 264.75% to -$41.4 million in 2023, then rose by 26.04% to -$30.6 million in 2024, then sank by 1301.7% to -$429.1 million in 2025, then surged by 93.79% to -$26.6 million in 2026.
• Per Business Quant, the three latest EVH Net Income towards Common Stockholders figures stand at -$26.6 million (Q1 2026), -$429.1 million (Q4 2025), and -$26.9 million (Q3 2025).